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ABSTRACT 
 
  
Purpose 
To evaluate the impact of a ureteral access sheath (UAS) on stone-free (SF) rate after 
flexible ureteroscopy for upper urinary tract stones. 
  
Materials and methods  
We retrospectively reviewed 280 patients who underwent flexible ureteroscopy (URS) 
for upper urinary tract stone between 2009 and 2012. Patients were divided into two groups 
based on whether a UAS was used (n=157) or not (n=123). SF rate was evaluated at one and 
three months after surgery by abdominal imaging. Quantitative and qualitative variables were 
compared with Student t test and χ2 test, respectively. A logistic regression model was used to 
determine the predictive factors of SF status.  
 
Results  
Stone size was similar in both groups (15.1 mm vs. 13.7 mm, p=0.21). SF rates at one 
and three months were comparable in UAS and non UAS groups (76% vs. 78% and 86% vs. 
87%, p=0.88 and 0.89, respectively). Complication rates were similar in both groups (12,7% 
vs. 12,1%, p=0,78). In multivariable analysis, stone size was the only predictive factor of SF 
rate (p=0.016). 
 
Conclusion:  
The routine use of a UAS did not improve SF rate in patients undergoing flexible URS 
for upper urinary tract calculi. 
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INTRODUCTION 
 
Over the last 10 years, flexible ureterorenoscopy (URS) has become an increasingly 
important option for the treatment of ureteral and kidney stones. Although there is no precise 
recommendation, concomitant use of a ureteral access sheath (UAS) has been advocated to: 1) 
facilitate the introduction of the ureteroscope and the extraction of small stone fragments 2) 
improve per-operative vision and 3) decrease intrarenal pressure 1-5. 
However, the systematic use of a UAS at the time of URS can be questioned. There is 
little if no evidence of improved operative outcomes after URS with the use of a UAS. Some 
authors reported an increased stone free (SF) rate 6 while others did not find any difference 
whether a UAS was used or not 4. Moreover, recent studies have shown that UAS could be 
responsible for ureteral injuries that can occur in up to 50% of the patients 7. 
In this context, our objective was to evaluate the impact of the use of a UAS on SF 
rate during flexible URS in patients treated for an upper tract stone.  
 
 
MATERIELS AND METHODS 
 We retrospectively collected the data of patients who underwent flexible URS at our 
institution between May 2009 and January 2012. We had a total of 359 cases.  We excluded 
URS performed in children (eight cases), URS made for the diagnosis and treatment of upper 
urinary tract urothelial tumours (10 cases), and patients who had several procedures for the 
same calculus (61 cases). This yielded a total of 280 flexible URS performed to treat a kidney 
or ureteral stone in one procedure. 
The following parameters were collected: age, sex, BMI, ASA score, stone size (larger 
diameter calculated on CT scan), number of stones, stone location (coded as ureter, pelvis, 
inferior calyx, medium calyx and upper calyx), operative time, fluoroscopy time, use of a 
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UAS, pre and post-operative stenting, occurrence of post operative complications (graded 
according to the Clavien system), and length of hospital stay.  
 SF status was evaluated at one month and three months using abdominal ultrasound or 
CT scan. Based on most publications, we considered that the patient was SF if there was less 
than one residual fragment with a diameter < 3 mm.  
 Surgical technique. Our standard technique begins with rigid cystoscopy and 
placement of a 0.035 inch PTFE hydrophilic guide wire up to the kidney under fluoroscopic 
guidance. The use of a UAS is left at the surgeon discretion. We don’t routinely use a UAS 
unless we want to remove as many fragments as possible (such as in the case of infectious or 
cystine stone) or if the endoscope cannot pass the ureteral orifice. If needed, we use a 12-14 
Fr hydrophilic UAS (Flexor®, Cook medical, Limerick, Ireland). If we don’t use any UAS, 
the flexible ureteroscope is passed up to the kidney over the working guide wire under 
fluoroscopic guidance. Stones are fragmented with a 273µm holmium laser fibre into dust. 
We usually remove two fragments for stone analysis. At the end of the procedure, a double J 
stent can be placed according to surgeon’s impression. It is removed one week later in the 
absence of residual fragment.  
 Statistical analysis. We compared the two groups (with or without UAS) using 
Student t and χ2 test for quantitative and categorical variables, respectively. A logistic 
regression model was used to identify predictive factors of SF rate.  Statistical analysis was 
performed with SPSS 17.0 software. A p value < 0.05 was considered to be significant. 
 
 
RESULTS 
There were 280 flexible URS in 280 patients including 123 without UAS and 157 with 
UAS.  Patients’ and stones’ characteristics are listed in table 1. There was a larger proportion 
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of men in the UAS group (sex ratio 1.7 vs. 1, p=0.03). Stone sizes were similar in both groups 
but there was a tendency for an increased number of stones in the UAS group, although not 
significant (1.9 vs. 1.6, p=0.07). There were more ureteral stones in the non UAS group (30% 
vs. 9%, p < 0.001) but there were no differences in the repartition of kidney stones 
particularly for lower pole stones. Operative and post-operative characteristics for both groups 
are described in table 2. Operative time was 10 minutes shorter in the non UAS group (76 min 
vs. 86 min, p=0.06). 36% of the patients had a ureteral stent before flexible URS, 50% in the 
non UAS group vs. 24% in the UAS group (p < 0.001). The severity of postoperative 
complications was assessed according to the Clavien classification 8. Complications were 
mostly minor and there were no differences between UAS and non UAS groups (12.7% vs. 
12.1%, p=0.78). 
SF rates are described in table 3. Overall SF rates at one and three months were 
comparable with or without UAS (76% vs. 78% and 86% vs. 87%, p=0.88 and 0.89, 
respectively). Best results were obtained for ureteral and upper kidney stones and there were 
no differences according to stone location. When considering the SF rate at three months, 
stone size was the only independent predictive factor in multivariable analysis (p=0.016). Age 
(p=0,76), BMI (p=0,23), stone location, number of stones (0.7), use of a UAS (p=0,21), pre-
operative stenting (p=0.15) and postoperative stenting (p=0,26) had no impact on stone free 
rate (table 4).  
 
 
DISCUSSION 
 Recent advances in URS have transformed the management of urolithiasis 9. Smaller 
and more durable flexible endoscopes and new laser technology enable full access to the 
collecting system and vaporisation of any kind of stone 10,11. Flexible URS is performed at 
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many institutions worldwide and recommended as one of the treatments of choice for ureteral 
and kidney stones 12. According to European Association of Urology guidelines, flexible URS 
is recommended as first line treatment for kidney stones < 2 cm and as second line treatment 
in kidney stones > 2 cm in case of failure of percutaneous nephrolithotomy 13,14 
The use of a UAS has traditionally been advocated for flexible URS 15. UAS 
supposedly have some advantages: 1) they allow easy multiple access to the upper urinary 
tract and therefore significantly facilitate flexible URS 2) they are supposed to improve vision 
by optimizing irrigation flow and 3) they decrease intra renal pressure which could potentially 
diminish kidney injury 1-5. However, there is currently no official recommendation as to the 
use of a UAS during flexible URS. Furthermore, evidence on the impact of UAS on peri-
operative outcomes as well as SF rates is very limited 4,6. 
We did not find any difference in terms of SF rate between patients who had been treated with 
or without a UAS.  In multivariable analysis, stone size was the only predictive factor of SF 
rate (p=0.016). The use of a UAS, stone location and/or the number of stones had no impact 
on SF rate.  Few studies have previously addressed this issue. Kourambas and al found no 
difference in SF rates according to the use of a UAS (78% in the UAS group versus 85% in 
the non UAS group) 4.  On the contrary, others reported an improved SF rate when URS was 
performed with a UAS 6. However, this difference disappeared when groups were stratified by 
stone location, which was not the case in our study where we did not observe any difference 
in SF rate whatever the stone location.   
Proponents of UAS state that they can increase the irrigation flow thereby flushing 
stone fragments out 1. Our results do not support this hypothesis. In our practice, we fragment 
all stone burden in very small particles and do not try to remove every single stone fragment.  
Overall, our SF rates are similar to those recently published 6,12,16-18. Most of the 
studies published over the last 10 years report SF rates ranging from 79% to 100% 6,12,18. In a 
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recent review of the literature, Aboumarzouk reports a mean SF rate of 87.5% 16,17. These 
numbers must be analyzed with caution because there is no consensus on the precise 
definition of a residual fragment as well as a wide variability in imaging modalities used to 
evaluate stone clearance 19. We routinely evaluate stone clearance with a KUB and an 
abdominal ultrasound to avoid the unnecessary radiation of the CT scan. We arbitrarily chose 
a cut-off of 3 mm to define a residual stone fragment since those small stones are unlikely to 
become symptomatic 20-22 and we rather advise active metabolic evaluation and medical 
treatment to avoid recurrence 23. 
We did not observe any difference in terms of complications between UAS and non 
UAS patients. However, UAS can be responsible for per and postoperative complications 
such as ureteral perforation, mucosal injury, urinary extravasation, ureteral avulsion and 
ureteral stricture 2,24,25. According to a recent study in which the authors carefully examined 
ureteral integrity after the use of a UAS, there was an incidence of 50% of iatrogenic ureteral 
lesions 7. 
Two studies demonstrated that a UAS can reduce intrarenal pressure 3,5. Nevertheless, 
no impact on renal function preservation has been proven 3,5. On the contrary, Lallas and al 
demonstrated that UAS was associated with a transient decrease of ureteral blood flow 25, 
which could potentially lead to further ureteral stricture 26.  
There are some limitations to our study. This is a retrospective review from a single 
institution with a relatively small population. The choice of using a UAS is left at the 
surgeon’s discretion so there might be some selection biases even if we did not find any 
difference in terms of stone characteristics. The frequency of ureteral stones was more 
important in the non UAS group (30% vs. 9%), which might have indirectly improved the 
results of non-UAS patients. However, when comparing the sub-groups of patients with 
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stones only located in the kidney, we did not find any difference in terms of stone free rate 
(85% vs. 81%, p=0.7). 
 
 
CONCLUSION 
 In our experience the use of a UAS did not improve SF rate in patients undergoing 
flexible URS for upper urinary tract stone. The only predictive factor of SF status was stone 
size. These results must be confirmed by prospective randomized trials.
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Table 1: Patients and stones’ characteristics 
 
 UAS group Non UAS group P value 
N 157 123  
Mean Age ( SD) 50 ( 15.2) 52 ( 17.3) 0.34 
Sex ratio (M/F) 1.7 1 0.034 
BMI (kg/m²) ( SD) 24.9 ( 3.9) 26.5 ( 6.2) 0.026 
 
Mean number of 
stones ( SD) 1.92 (1.5) 1.61 (1.1) 0.07 
 
Mean stone size 
(cm  SD) 15.15 ( 9.8) 13.75 ( 8.0) 0.21 
Stone location    
Ureter 10 (9%) 27 (30%) < 0.001 
Upper-pole 8 (7%) 7 (8%) 0.91 
Mid-pole 17 (15%) 11 (12%) 0.48 
Lower-pole 48 (44%) 30 (33%) 0.11 
Renal pelvis 25 (23%) 14 (15%) 0.18 
BMI: Body Mass Index ; M: Male ; F: Female. 
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Table 2: Operative and post-operative outcomes 
 
 UAS group Non UAS group P value 
N 157 123  
 
Fluoroscopy time (sec) 
( SD) 117 (119) 92 ( 88) 0.1 
 
Lenght of stay (days) ( 
SD) 
2.04 ( 1.2) 2.01 ( 1.5) 0.86 
 
Mean operative time 
(min) (SD) 86 ( 37) 76 ( 36) 0.06 
Pre-operative urétéral 
stent 
39 (24%) 62 (50%) < 0.001 
 
Post-operative ureteral 
stent 
134 (85%) 94 (76%) 0.61 
 
Overall post-operative 
complications 
20 (12,7%) 15 (12,1%) 0.78 
Minor complications 16 (10%) 12 (9%) 0.98 
Major complications 4 (2.5%) 3 (2.4%) 0.99 
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Table 3: SF rates at three months according to stone location. 
 
 UAS group Non UAS group P value 
Overall 86 87 0.89 
Ureter 100 96 0.53 
Overall kidney 85 81 0.67 
Renal pelvis  96 92 0.66 
Lower pole 79 80 0.92 
Mid pole 88 81 0.63 
Upper pole 100 85 0.26 
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Table 4: Multivariable analysis: predictive factors of SF rate at three months 
 
Variables p 
Age 0.76 
BMI 0.23 
Stone size 0.016 
Number of stones 0.7 
UAS (yes/no) 0.21 
Pre operative stent 0.15 
Post operative stent 0.26 
Stone location 0.21 
  
 
